Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00613
|
|||||
| Drug Name |
Dipyridamole
|
|||||
| Synonyms |
2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; Agilease; Anginal; Antistenocardin; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Apotex Brand of Dipyridamole; Apricor; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Berlin-Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Cleridium 150; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; D 9766; Dipiridamol; Dipiridamol [INN-Spanish]; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Dipyridamolum; Dipyridamolum [INN-Latin]; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; IPRAD Brand of Dipyridamole; Iv Persantine; Justpertin; Kurantil; Miosen; Natyl; Novo-Dipiradol; Novopharm Brand of Dipyridamole; Peridamol; Permiltin; Permole, Persantine, Dipyridan, Dipyridamole; Persantin; Persantine; Persantine (TN); Piroan; Prandiol; Prandiol 75; Protangix; RA-8; Stenocardil; Stenocardiol; Stimolcardio; Usaf Ge-12
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11:BA00] | Approved | [1] | |||
| Therapeutic Class |
Vasodilator Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H40N8O4
|
|||||
| Canonical SMILES |
C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
|
|||||
| InChI |
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
|
|||||
| InChIKey |
IZEKFCXSFNUWAM-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 58-32-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 504.6 | Topological Polar Surface Area | 145 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 12 | |||
| XLogP |
0.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321246
,10528232
,10589644
,11111116
,11111117
,11113358
,11335871
,11361110
,11363898
,11366460
,11369022
,11371244
,11374262
,11377184
,11410079
,11462082
,11466170
,11467290
,11484739
,11485919
,11488788
,11490218
,11492337
,11494818
,12054904
,14811101
,17405027
,22391481
,24277705
,26611713
,26680947
,26747068
,26747069
,26751580
,26751581
,26758633
,29222251
,46487910
,46506292
,47291146
,47291147
,480294
,489152
,5052822
,612448
,7847368
,7979106
,8149314
,8151978
,855977
|
|||||
| ChEBI ID |
ChEBI:4653
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Dipyridamole was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13. | |||||
| 3 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.